Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in <i>CTNNB1</i> -mutated endometrial cancerBradley R. Corr, Benjamin G. Bitler|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 6